Additive effects of intravenous and intravesical application of vibegron, a β3-adrenoceptor agonist, on bladder function in rats with bladder overactivity
- 18 June 2020
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 393 (11) , 2073-2080
Abstract
To examine the effects of intravenous and intravesical application of vibegron, a new β3-adrenoceptor (β3-AR) agonist, on bladder function in rats with oxotremorine methiodide (oxo-M: a nonselective muscarinic receptor agonist)-induced bladder overactivity. Cystometry was performed in conscious female rats with intravesical instillation of oxo-M (200 μM). In oxo-M-treated rats, vehicle or vibegron (1 and 10 mg/kg) was cumulatively applied intravenously at 30-min intervals. In other groups of rats, oxo-M + vehicle or oxo-M + vibegron (10, 100 μM, and 1 mM) was cumulatively instilled intravesically at 60-min intervals followed by intravenous application of vibegron (10 mg/kg). Expression of β3-ARs in the bladder was also evaluated using immunohistochemical staining. Intravenous application of vibegron (10 mg/kg) significantly increased bladder capacity (1.3 times) and decreased baseline, threshold, and maximal voiding pressure compared with vehicle. Next, intravesical application of vibegron (1 mM) significantly increased threshold pressure and bladder capacity (1.2 times) compared with vehicle. Combined treatments of intravesical (1 mM) and intravenous (10 mg/kg) application of vibegron induced a significantly larger degree of increases in bladder capacity (1.4 times) compared with vehicle. In addition, β3-ARs were expressed throughout the rat bladder, mainly in the urothelium. These results suggest that vibegron excreted in urine as an unchanged compound can induce the additive inhibitory effects on bladder overactivity possibly through urothelial β3-AR activation, which inhibits the afferent limb of micturition reflex rather than the efferent function as evidenced by the increases in threshold pressure and bladder capacity without affecting bladder contractile function after intravesical vibegron application.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP18K09152)
This publication has 15 references indexed in Scilit:
- β3‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?British Journal of Pharmacology, 2019
- Beta‐3 adrenergic receptor is expressed in acetylcholine‐containing nerve fibers of the human urinary bladder: An immunohistochemical studyNeurourology and Urodynamics, 2017
- Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral LigationThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Combination therapy with β3‐adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivityInternational Journal of Urology, 2016
- Discovery of Vibegron: A Potent and Selective β3Adrenergic Receptor Agonist for the Treatment of Overactive BladderJournal of Medicinal Chemistry, 2016
- Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [3H]-acetylcholine release experiments in the isolated detrusorEuropean Journal of Pharmacology, 2015
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndromeNaunyn-Schmiedeberg's Archives of Pharmacology, 2012
- Urothelial beta‐3 adrenergic receptors in the rat bladderNeurourology and Urodynamics, 2010
- β−Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladderCell and tissue research, 2010
- β-Adrenoceptor Agonists Stimulate Endothelial Nitric Oxide Synthase in Rat Urinary Bladder Urothelial CellsJournal of Neuroscience, 2002